Day One focuses on the development of targeted therapies for the treatment of cancer in indications with a high unmet medical need. Our primary focus is to complete rigorous clinical trials and obtain regulatory approval to make this therapy available to the patient community as quickly as possible.

As such, we are not currently offering expanded access to our investigational products, including emiltatug ledadotin (Eli-Le). Participation in our clinical trials is the most appropriate way to access treatment at this time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

Information about our clinical trials, including eligibility criteria and locations, is available at https://www.clinicaltrials.gov.

If you have additional questions, please contact your physician or [email protected]. For inquiries regarding tovorafenib access outside the U.S., please contact [email protected].